Internal Medicine, Hematology & Oncology · Orange City, FL
NPI
1316320179
Since 2015
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2776 Enterprise Rd
Orange City, FL, 32763
Phone (347) 737-1349
Groups this clinician bills Medicare through
Medicare paid, 2024
$714K
68,311 services
Medicare patients, 2024
431
Average age 76
Drug cost, 2024
$4.6M
1,434 prescriptions
Company payments, 2025
$419
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel Castro was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 8,164 times for 11 patients. In total Daniel Castro billed 68,311 services in 127 codes, and Medicare paid $714K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 8,164 | 11 | $0.30 | $2,411 |
| J0897 Injection, denosumab, 1 mg | Office | 4,323 | 26 | $20.87 | $90K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2,160 | 20 | $0.11 | $227 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,313 | 15 | $0.09 | $117 |
| 85025 Blood Count | Office | 516 | 225 | $7.61 | $3,927 |
| 36415 Venipuncture Blood Collection | Office | 464 | 230 | $8.56 | $3,971 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 373 | 15 | $0.79 | $293 |
| 84100 Clinical Chemistry | Office | 342 | 175 | $4.65 | $1,590 |
| 80053 Clinical Chemistry | Office | 336 | 174 | $10.35 | $3,478 |
| 99213 Office E&M - Established | Office | 249 | 173 | $66.73 | $17K |
| 96367 Intravenous Infusion, Hydration | Office | 224 | 26 | $20.83 | $4,667 |
| 96372 Injection Administration | Office | 202 | 76 | $10.85 | $2,191 |
| 82607 Clinical Chemistry | Office | 153 | 113 | $14.78 | $2,261 |
| 82746 Clinical Chemistry | Office | 153 | 113 | $14.41 | $2,205 |
| 82728 Clinical Chemistry | Office | 151 | 110 | $13.36 | $2,017 |
By year: 2022 $9,030 for 1,004 services; 2023 $2,957 for 602 services; 2024 $714K for 68,311 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 516 | 225 | $7.61 | $3,927 |
| 36415 Venipuncture Blood Collection | 464 | 230 | $8.56 | $3,971 |
| 84100 Clinical Chemistry | 342 | 175 | $4.65 | $1,590 |
| 80053 Clinical Chemistry | 336 | 174 | $10.35 | $3,478 |
| 82607 Clinical Chemistry | 153 | 113 | $14.78 | $2,261 |
| 82746 Clinical Chemistry | 153 | 113 | $14.41 | $2,205 |
| 83540 Clinical Chemistry | 151 | 110 | $6.34 | $957 |
| 82728 Clinical Chemistry | 151 | 110 | $13.36 | $2,017 |
| 83550 Clinical Chemistry | 151 | 110 | $8.57 | $1,294 |
| 85610 Clinical Chemistry | 78 | 12 | $4.20 | $328 |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel Castro prescribed most often to Medicare patients was Eliquis (Apixaban), with 114 prescriptions and refills. In total Daniel Castro wrote 1,434 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 114 | 230 | 39 | $130K |
| Letrozole Generic | 76 | 188 | 25 | $1,447 |
| Anastrozole Generic | 71 | 184 | 22 | $1,209 |
| Xarelto Rivaroxaban | 70 | 117 | 22 | $61K |
| Palonosetron Hcl Generic | 49 | 49 | 22 | $1,882 |
| Dexamethasone Generic | 47 | 48 | 17 | $832 |
| Xgeva Denosumab | 42 | 42 | Under 11 | $132K |
| Ondansetron Odt Ondansetron | 37 | 39 | 29 | $1,575 |
| Warfarin Sodium Generic | 36 | 78 | Under 11 | $312 |
| Imfinzi Durvalumab | 35 | 35 | Under 11 | $369K |
| Prochlorperazine Maleate Generic | 31 | 31 | 22 | $621 |
| Imbruvica Ibrutinib | 28 | 28 | Under 11 | $436K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 27 | 33 | Under 11 | $215 |
| Lenalidomide Generic | 26 | 26 | Under 11 | $326K |
| Udenyca Pegfilgrastim-Cbqv | 23 | 23 | Under 11 | $90K |
Brand drugs: - claims; generic drugs: 777 claims; opioid claims: 57.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel Castro $419 ($419 in general payments such as food, travel and fees) from 12 companies. The largest payer was Dendreon Pharmaceuticals LLC with $73.95.
| Company | Payments | Amount |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 3 | $73.95 |
| Caris MPI, Inc. | 3 | $69.28 |
| Janssen Biotech, Inc. JNJ | 3 | $56.26 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $42.5 |
| Celgene Corporation BMY | 1 | $27.09 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $26.83 |
| Geron Corporation GERN | 1 | $25.01 |
| Daiichi Sankyo Inc. 4568.T | 1 | $22.26 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $19.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.